Experienced in Porphyria

Dr. Xin Yao

Oncology | Hematology
Martin Memorial Physician Corporation Inc
501 Se Osceola St, Suite 301, 
Stuart, FL 
 (1734.8 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Porphyria
Martin Memorial Physician Corporation Inc
501 Se Osceola St, Suite 301, 
Stuart, FL 
 (1734.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Xin Yao is an Oncologist and a Hematologist in Stuart, Florida. MD. Yao and is rated as an Experienced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Lung Adenocarcinoma, and Thrombocytopenia. MD. Yao is currently accepting new patients.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Thedacare Regional Medical Center - Appleton Inc
Cleveland Clinic Martin North Hospital
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  Humana
  •  Florida Blue

Locations

MARTIN MEMORIAL PHYSICIAN CORPORATION INC
501 Se Osceola St, Suite 301, Stuart, FL 34994

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
View 6 Less Clinical Trials

62 Total Publications

Risk assessment and management strategy of two new Nitrosamine Drug Substance Related Impurities (NDSRIs) in a pharmaceutical drug product for the treatment of a rare disease- From prediction to control.
Risk assessment and management strategy of two new Nitrosamine Drug Substance Related Impurities (NDSRIs) in a pharmaceutical drug product for the treatment of a rare disease- From prediction to control.
Journal: Journal of pharmaceutical sciences
Published: October 22, 2024
Similar Doctors
Advanced in Porphyria
Dr. Debra S. Brandt
Hematology Oncology | Hematology | Oncology
Advanced in Porphyria
Dr. Debra S. Brandt
Hematology Oncology | Hematology | Oncology

Jupiter Medical Center Physicians Group Inc

1240 S Old Dixie Hwy, 
Jupiter, FL 
 (21.2 mi)
561-263-4400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Debra Brandt is a Hematologist Oncology specialist and a Hematologist in Jupiter, Florida. Dr. Brandt and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), Familial Colorectal Cancer, and Angiosarcoma. Dr. Brandt is currently accepting new patients.

Experienced in Porphyria
Dr. Hilary I. Gomolin
Oncology | Hematology
Experienced in Porphyria
Dr. Hilary I. Gomolin
Oncology | Hematology

Brrh Oncology, LLC

701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
 (58.4 mi)
561-955-6400
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Hilary Gomolin is an Oncologist and a Hematologist in Boca Raton, Florida. Dr. Gomolin and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. His top areas of expertise are Non-Hodgkin Lymphoma, Anemia, Thrombocytopenia, and Gastric Lymphoma. Dr. Gomolin is currently accepting new patients.

Experienced in Porphyria
Dr. Jon S. Dubois
Hematology Oncology | Hematology | Oncology
Experienced in Porphyria
Dr. Jon S. Dubois
Hematology Oncology | Hematology | Oncology

Jupiter Medical Center Physicians Group Inc

1210s Old Dixie Hwy, 
Jupiter, FL 
 (21.1 mi)
561-747-2234
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jon Dubois is a Hematologist Oncology specialist and a Hematologist in Jupiter, Florida. Dr. Dubois and is rated as a Distinguished provider by MediFind in the treatment of Porphyria. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Pancreatic Ductal Adenocarcinoma. Dr. Dubois is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile